Skip to main content

$17.88 -0.10 (-0.56%)

High

$18.20

Low

$17.50

Trades

1,245

Turnover

$1,190,837

Volume

66,664
30 June 2023 at 4:10pm
Register to track CUV and receive email alerts.

First vitiligo patient enrolled in monotherapy study

StockBot

416,823 posts

CUV released this announcement to the ASX on 20 October 2022, 9:54. The announcement is not marked as price sensitive, and is 3 page(s) in length and 151.05kb in size.

You can view all announcements from CUV and see how they appear on a price chart on the announcements page.

At the date of this announcement, CUV was 6.043% short sold according to ASIC data. It was ranked the 31st most shorted stock on the ASX. It remains ranked 38th as of the latest reported data (05 May 2025).

Other Recent Announcements from CUV
Notification regarding unquoted securities - CUV 30 June 2023, 11:51
Two Grounds of Appeal Upheld by NICE Panel 30 June 2023, 9:17
Notification of cessation of securities - CUV 29 June 2023, 11:44
First vitiligo patient enrolled in monotherapy study 20 October 2022, 9:54
Investor Presentation - Sydney 14 October 2022, 9:27
Notice of Annual General Meeting/Proxy Form 23 September 2022, 9:17
Strategic Update V 19 September 2022, 9:23
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track CUV and receive email alerts.